Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery

Fuyuhiko Motoi, Michiaki Unno, Hidenori Takahashi, Takaho Okada, Keita Wada, Masayuki Sho, Hiroaki Nagano, Ippei Matsumoto, Sohei Satoi, Yoshiaki Murakami, Masashi Kishiwada, Goro Honda, Hisafumi Kinoshita, Hideo Baba, Shoichi Hishinuma, Minoru Kitago, Hidehiro Tajima, Hiroyuki Shinchi, Hiroshi Takamori, Tomoo KosugeHiroki Yamaue, Tadahiro Takada

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background Little is known about the effects of neoadjuvant therapy on outcomes in patients with pancreatic cancer. This study evaluated the effects of neoadjuvant therapy on resectability and perioperative outcomes. Methods A total of 992 patients were enrolled, with 971 deemed eligible. Of these, 582 had resectable tumors and 389 had borderline resectable tumors, and 388 patients received neoadjuvant therapy. Demographic characteristics and peri- and postoperative parameters were assessed by a questionnaire survey. Results The R0 rate was significantly higher in patients with resectable tumors who received neoadjuvant therapy than in those who underwent surgery first, but no significant difference was noted in patients with borderline resectable tumors. Operation time was significantly longer and blood loss was significantly greater in patients who received neoadjuvant therapy than in those who underwent surgery first, but there were no significant differences in specific complications and mortality rates. The node positivity rate was significantly lower in the neoadjuvant than in the surgery-first group, indicating that the former had significantly lower stage tumors. Conclusions Neoadjuvant therapy may not increase the mortality and morbidity rate and may be able to increase the chance for curative resection against resectable tumor.

Original languageEnglish
Pages (from-to)148-158
Number of pages11
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume21
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Neoplasms
Therapeutics
Mortality
Demography
Morbidity

Keywords

  • Neoadjuvant
  • Pancreatic cancer
  • Perioperative outcome
  • Resectability
  • Surgery

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. / Motoi, Fuyuhiko; Unno, Michiaki; Takahashi, Hidenori; Okada, Takaho; Wada, Keita; Sho, Masayuki; Nagano, Hiroaki; Matsumoto, Ippei; Satoi, Sohei; Murakami, Yoshiaki; Kishiwada, Masashi; Honda, Goro; Kinoshita, Hisafumi; Baba, Hideo; Hishinuma, Shoichi; Kitago, Minoru; Tajima, Hidehiro; Shinchi, Hiroyuki; Takamori, Hiroshi; Kosuge, Tomoo; Yamaue, Hiroki; Takada, Tadahiro.

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 21, No. 2, 2014, p. 148-158.

Research output: Contribution to journalArticle

Motoi, F, Unno, M, Takahashi, H, Okada, T, Wada, K, Sho, M, Nagano, H, Matsumoto, I, Satoi, S, Murakami, Y, Kishiwada, M, Honda, G, Kinoshita, H, Baba, H, Hishinuma, S, Kitago, M, Tajima, H, Shinchi, H, Takamori, H, Kosuge, T, Yamaue, H & Takada, T 2014, 'Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery', Journal of Hepato-Biliary-Pancreatic Sciences, vol. 21, no. 2, pp. 148-158. https://doi.org/10.1002/jhbp.15
Motoi, Fuyuhiko ; Unno, Michiaki ; Takahashi, Hidenori ; Okada, Takaho ; Wada, Keita ; Sho, Masayuki ; Nagano, Hiroaki ; Matsumoto, Ippei ; Satoi, Sohei ; Murakami, Yoshiaki ; Kishiwada, Masashi ; Honda, Goro ; Kinoshita, Hisafumi ; Baba, Hideo ; Hishinuma, Shoichi ; Kitago, Minoru ; Tajima, Hidehiro ; Shinchi, Hiroyuki ; Takamori, Hiroshi ; Kosuge, Tomoo ; Yamaue, Hiroki ; Takada, Tadahiro. / Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. In: Journal of Hepato-Biliary-Pancreatic Sciences. 2014 ; Vol. 21, No. 2. pp. 148-158.
@article{3b8865ce84e24811b5e2c72772664f06,
title = "Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery",
abstract = "Background Little is known about the effects of neoadjuvant therapy on outcomes in patients with pancreatic cancer. This study evaluated the effects of neoadjuvant therapy on resectability and perioperative outcomes. Methods A total of 992 patients were enrolled, with 971 deemed eligible. Of these, 582 had resectable tumors and 389 had borderline resectable tumors, and 388 patients received neoadjuvant therapy. Demographic characteristics and peri- and postoperative parameters were assessed by a questionnaire survey. Results The R0 rate was significantly higher in patients with resectable tumors who received neoadjuvant therapy than in those who underwent surgery first, but no significant difference was noted in patients with borderline resectable tumors. Operation time was significantly longer and blood loss was significantly greater in patients who received neoadjuvant therapy than in those who underwent surgery first, but there were no significant differences in specific complications and mortality rates. The node positivity rate was significantly lower in the neoadjuvant than in the surgery-first group, indicating that the former had significantly lower stage tumors. Conclusions Neoadjuvant therapy may not increase the mortality and morbidity rate and may be able to increase the chance for curative resection against resectable tumor.",
keywords = "Neoadjuvant, Pancreatic cancer, Perioperative outcome, Resectability, Surgery",
author = "Fuyuhiko Motoi and Michiaki Unno and Hidenori Takahashi and Takaho Okada and Keita Wada and Masayuki Sho and Hiroaki Nagano and Ippei Matsumoto and Sohei Satoi and Yoshiaki Murakami and Masashi Kishiwada and Goro Honda and Hisafumi Kinoshita and Hideo Baba and Shoichi Hishinuma and Minoru Kitago and Hidehiro Tajima and Hiroyuki Shinchi and Hiroshi Takamori and Tomoo Kosuge and Hiroki Yamaue and Tadahiro Takada",
year = "2014",
doi = "10.1002/jhbp.15",
language = "English",
volume = "21",
pages = "148--158",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer

T2 - Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery

AU - Motoi, Fuyuhiko

AU - Unno, Michiaki

AU - Takahashi, Hidenori

AU - Okada, Takaho

AU - Wada, Keita

AU - Sho, Masayuki

AU - Nagano, Hiroaki

AU - Matsumoto, Ippei

AU - Satoi, Sohei

AU - Murakami, Yoshiaki

AU - Kishiwada, Masashi

AU - Honda, Goro

AU - Kinoshita, Hisafumi

AU - Baba, Hideo

AU - Hishinuma, Shoichi

AU - Kitago, Minoru

AU - Tajima, Hidehiro

AU - Shinchi, Hiroyuki

AU - Takamori, Hiroshi

AU - Kosuge, Tomoo

AU - Yamaue, Hiroki

AU - Takada, Tadahiro

PY - 2014

Y1 - 2014

N2 - Background Little is known about the effects of neoadjuvant therapy on outcomes in patients with pancreatic cancer. This study evaluated the effects of neoadjuvant therapy on resectability and perioperative outcomes. Methods A total of 992 patients were enrolled, with 971 deemed eligible. Of these, 582 had resectable tumors and 389 had borderline resectable tumors, and 388 patients received neoadjuvant therapy. Demographic characteristics and peri- and postoperative parameters were assessed by a questionnaire survey. Results The R0 rate was significantly higher in patients with resectable tumors who received neoadjuvant therapy than in those who underwent surgery first, but no significant difference was noted in patients with borderline resectable tumors. Operation time was significantly longer and blood loss was significantly greater in patients who received neoadjuvant therapy than in those who underwent surgery first, but there were no significant differences in specific complications and mortality rates. The node positivity rate was significantly lower in the neoadjuvant than in the surgery-first group, indicating that the former had significantly lower stage tumors. Conclusions Neoadjuvant therapy may not increase the mortality and morbidity rate and may be able to increase the chance for curative resection against resectable tumor.

AB - Background Little is known about the effects of neoadjuvant therapy on outcomes in patients with pancreatic cancer. This study evaluated the effects of neoadjuvant therapy on resectability and perioperative outcomes. Methods A total of 992 patients were enrolled, with 971 deemed eligible. Of these, 582 had resectable tumors and 389 had borderline resectable tumors, and 388 patients received neoadjuvant therapy. Demographic characteristics and peri- and postoperative parameters were assessed by a questionnaire survey. Results The R0 rate was significantly higher in patients with resectable tumors who received neoadjuvant therapy than in those who underwent surgery first, but no significant difference was noted in patients with borderline resectable tumors. Operation time was significantly longer and blood loss was significantly greater in patients who received neoadjuvant therapy than in those who underwent surgery first, but there were no significant differences in specific complications and mortality rates. The node positivity rate was significantly lower in the neoadjuvant than in the surgery-first group, indicating that the former had significantly lower stage tumors. Conclusions Neoadjuvant therapy may not increase the mortality and morbidity rate and may be able to increase the chance for curative resection against resectable tumor.

KW - Neoadjuvant

KW - Pancreatic cancer

KW - Perioperative outcome

KW - Resectability

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84897082482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897082482&partnerID=8YFLogxK

U2 - 10.1002/jhbp.15

DO - 10.1002/jhbp.15

M3 - Article

C2 - 23913634

AN - SCOPUS:84897082482

VL - 21

SP - 148

EP - 158

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 2

ER -